Kintara Therapeutics, Inc. (KTRA) News
Filter KTRA News Items
KTRA News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
KTRA News Highlights
- KTRA's 30 day story count now stands at 2.
- Over the past 2 days, the trend for KTRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest KTRA News From Around the Web
Below are the latest news stories about KINTARA THERAPEUTICS INC that investors may wish to consider to help them evaluate KTRA as an investment opportunity.
Kintara Therapeutics Announces Review of Strategic AlternativesKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value. |
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing RequirementKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it received notice from the Staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b) (the "Rule"). The Rule requires a minimum $2,500,000 stockholders |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! |
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate UpdateKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2023 and provided a corporate update. |
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE StudyKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the curre |
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth ConferenceKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and CEO, Robert E. Hoffman will present at the 8th Annual Dawson James Small Cap Growth Conference on Thursday, October 12, 2023 at 10:30 am ET. |
Kintara Therapeutics to Present at the LD Micro Main Event XVI ConferenceKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and CEO, Robert E. Hoffman will present in the LD Micro Main Event XVI Conference on Wednesday, October 4, 2023 at 11:30 am PT at the Luxe Sunset Boulevard Hotel in Los Angeles, California. |
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual MeetingKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, today announced the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam. Presented on September 23, the poster focused on two patient cases from Kintara's Phase 2 study evaluating the safety and tolerability of VAL-083 when administered concurrentl |
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceJUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consu |
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate UpdateKintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2023 and provided a corporate update. |